IL154553A0 - Urocortin-iii and uses thereof - Google Patents

Urocortin-iii and uses thereof

Info

Publication number
IL154553A0
IL154553A0 IL15455302A IL15455302A IL154553A0 IL 154553 A0 IL154553 A0 IL 154553A0 IL 15455302 A IL15455302 A IL 15455302A IL 15455302 A IL15455302 A IL 15455302A IL 154553 A0 IL154553 A0 IL 154553A0
Authority
IL
Israel
Prior art keywords
urocortin
iii
Prior art date
Application number
IL15455302A
Other languages
English (en)
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of IL154553A0 publication Critical patent/IL154553A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
IL15455302A 2001-03-15 2002-03-15 Urocortin-iii and uses thereof IL154553A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27606901P 2001-03-15 2001-03-15
US29491401P 2001-05-31 2001-05-31
PCT/US2002/009115 WO2002074326A2 (en) 2001-03-15 2002-03-15 Urocortin-iii and uses thereof

Publications (1)

Publication Number Publication Date
IL154553A0 true IL154553A0 (en) 2003-09-17

Family

ID=26957747

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15455302A IL154553A0 (en) 2001-03-15 2002-03-15 Urocortin-iii and uses thereof
IL154553A IL154553A (en) 2001-03-15 2003-02-20 Human urocortin III and its use in the preparation of a drug for the treatment of a pathophysiological condition

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154553A IL154553A (en) 2001-03-15 2003-02-20 Human urocortin III and its use in the preparation of a drug for the treatment of a pathophysiological condition

Country Status (10)

Country Link
US (8) US6812210B2 (xx)
EP (1) EP1368051A4 (xx)
JP (1) JP4472256B2 (xx)
AU (2) AU2002306853B2 (xx)
CA (1) CA2425902C (xx)
IL (2) IL154553A0 (xx)
NZ (1) NZ524477A (xx)
RU (2) RU2305109C2 (xx)
WO (1) WO2002074326A2 (xx)
ZA (1) ZA200209934B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
RU2305109C2 (ru) 2001-03-15 2007-08-27 Рисерч Дивелопмент Фаундейшн Урокортин iii, его аналог (варианты) и фармацевтическая композиция
US7879111B2 (en) * 2006-11-02 2011-02-01 Sony Corporation System and method for RFID transfer of MAC, keys
CA2468991A1 (en) 2001-12-03 2003-06-12 Metabolex, Inc. Methods and reagents for diagnosis and treatment of diabetes
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
WO2008109432A2 (en) * 2007-03-02 2008-09-12 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using sirna in neutral liposomes
CA2692039C (en) * 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
US20100197588A1 (en) * 2007-09-11 2010-08-05 Dorian Bevec Use of a peptide as a therapeutic agent
US20100216722A1 (en) * 2007-09-11 2010-08-26 Dorian Bevec Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
HUP0800527A2 (en) * 2008-08-22 2011-03-28 Univ Szegedi Urocortine 3 fragments and analogues, process for their preparation and use for the treatment of depression and anxiety
CA2742710A1 (en) * 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
ES2545794T3 (es) 2009-08-28 2015-09-15 Research Development Foundation Análogos de urocortina 2 y usos de los mismos
US20110105397A1 (en) * 2009-11-04 2011-05-05 Gengo Peter J Method for treating heart failure with stresscopin-like peptides
US9314506B2 (en) 2011-10-24 2016-04-19 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
BR112016022854A2 (pt) * 2014-04-03 2018-01-16 Univ California método para tratar, aliviar ou proteger (prevenir), diminuir o progresso ou reverter uma doença, método para tratar, aliviar ou proteger (prevenir) uma doença, uso, e, ácido nucleico ou gene
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
KR20190060642A (ko) * 2017-11-24 2019-06-03 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 심부전의 예방 또는 치료용 의약

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223792A1 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) * 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
US5959109A (en) * 1996-05-15 1999-09-28 Neurocrine Biosciences, Inc. Compounds and methods for increasing endogenous levels of corticotropin-releasing factor
CN1161614C (zh) * 1998-03-30 2004-08-11 研究发展基金会 用促肾上腺皮质素释放因子受体-1缺陷型小鼠鉴定促效剂和拮抗剂的方法
GB9807504D0 (en) 1998-04-07 1998-06-10 Univ London Use of corticotropin releasing hormone and like polypeptides in therapy
US20040034882A1 (en) * 1999-07-15 2004-02-19 Vale Wylie W. Corticotropin releasing factor receptor 2 deficient mice and uses thereof
NZ516611A (en) * 1999-07-15 2003-09-26 Res Dev Foundation Mice that are homozygously deficient in CRFR2 and uses thereof in drug screening
US7674463B1 (en) 1999-07-15 2010-03-09 Research Development Foundation Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist
DK1305334T3 (da) * 2000-08-04 2009-02-02 Res Dev Foundation Urocortinproteiner og anvendelser deraf
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
RU2305109C2 (ru) * 2001-03-15 2007-08-27 Рисерч Дивелопмент Фаундейшн Урокортин iii, его аналог (варианты) и фармацевтическая композиция
CA2468991A1 (en) * 2001-12-03 2003-06-12 Metabolex, Inc. Methods and reagents for diagnosis and treatment of diabetes
WO2004029081A2 (en) 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
BR112016022854A2 (pt) * 2014-04-03 2018-01-16 Univ California método para tratar, aliviar ou proteger (prevenir), diminuir o progresso ou reverter uma doença, método para tratar, aliviar ou proteger (prevenir) uma doença, uso, e, ácido nucleico ou gene

Also Published As

Publication number Publication date
ZA200209934B (en) 2006-06-28
RU2305109C2 (ru) 2007-08-27
RU2003104977A (ru) 2005-01-20
AU2006225288C1 (en) 2009-09-17
US20140004603A1 (en) 2014-01-02
US20040143095A1 (en) 2004-07-22
US20160375102A1 (en) 2016-12-29
US6953838B2 (en) 2005-10-11
US6812210B2 (en) 2004-11-02
AU2002306853B2 (en) 2006-07-06
IL154553A (en) 2011-03-31
JP4472256B2 (ja) 2010-06-02
AU2006225288B2 (en) 2009-03-19
US9388229B2 (en) 2016-07-12
WO2002074326A2 (en) 2002-09-26
US20090156493A1 (en) 2009-06-18
US8669092B2 (en) 2014-03-11
US20030036507A1 (en) 2003-02-20
AU2006225288A1 (en) 2006-10-26
US20120270792A1 (en) 2012-10-25
NZ524477A (en) 2004-11-26
CA2425902C (en) 2017-01-03
JP2005505244A (ja) 2005-02-24
US20140288161A1 (en) 2014-09-25
US8445425B2 (en) 2013-05-21
RU2007110981A (ru) 2008-10-10
EP1368051A4 (en) 2005-11-02
US8084413B2 (en) 2011-12-27
US20060003937A1 (en) 2006-01-05
EP1368051A2 (en) 2003-12-10
WO2002074326A3 (en) 2002-11-14
US7459427B2 (en) 2008-12-02
CA2425902A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
EP1463742A4 (en) NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
EP1539941A4 (en) ADZYMES AND THEIR USES
AU9667901A (en) Mycoattractants and mycopesticides
EP1408980A4 (en) NEW QUINAZOLINES AND THEIR USE
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
HUP0500989A2 (en) Animicrobial polypeptides and their uses
EP1408978A4 (en) NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
EP1408971A4 (en) NEW QUINOLINES AND THEIR USES
IL154553A0 (en) Urocortin-iii and uses thereof
EP1434772A4 (en) CONNECTIONS AND METHODS
EP1414848A4 (en) REPLICINE PEPTIDES AND ITS USES
EP1419175A4 (en) PEPTIDES OF REPLIKIN AND THEIR USE
AU2002359694A8 (en) Compounds and methods
GB0126889D0 (en) Compounds and their uses
EP1408985A4 (en) NEW PYRIDOPYRIMIDONE AND ITS USES
EP1392317A4 (en) SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
EP1379228A4 (en) (Z) -STYRYLBENZYLSULPONES AND THEIR PHARMACEUTICAL APPLICATIONS
EP1404670A4 (en) SEMICARBAZIDES AND THEIR USE
AU2003231827A8 (en) Pseudo-tissues and uses thereof
PL363290A1 (en) 1k-polyurethane lacquer and use thereof
PL370031A1 (en) Novel amylases and uses thereof
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
EP1379240A4 (en) CONNECTIONS AND METHODS
EP1367123A4 (en) NEUROTONIN AND ITS USE

Legal Events

Date Code Title Description
FF Patent granted